[{"id":"149819dc-f2ee-4b82-83e1-8c607402853f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909777","created_at":"2021-01-18T14:16:53.862Z","updated_at":"2025-02-25T14:50:16.761Z","phase":"Phase 1","brief_title":"Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma","source_id_and_acronym":"NCT02909777","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fimepinostat (CUDC-907)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-13"},{"id":"340d554a-da42-467e-b75a-aa5b0eadce3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02674750","created_at":"2021-01-18T13:02:24.886Z","updated_at":"2024-07-02T16:36:11.338Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations","source_id_and_acronym":"NCT02674750","lead_sponsor":"Curis, Inc.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fimepinostat (CUDC-907)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 05/28/2019","primary_completion_date":" 05/28/2019","study_txt":" Completion: 05/28/2019","study_completion_date":" 05/28/2019","last_update_posted":"2022-04-27"},{"id":"3e8d61ce-5436-4030-a690-3833bf9a750d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01742988","created_at":"2021-01-18T07:38:21.868Z","updated_at":"2024-07-02T16:36:30.660Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma","source_id_and_acronym":"NCT01742988","lead_sponsor":"Curis, Inc.","biomarkers":" MYC • BCL2 • BCL6 • CREBBP","pipe":" | ","alterations":" MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6 • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • fimepinostat (CUDC-907)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 10/09/2020","study_completion_date":" 10/09/2020","last_update_posted":"2021-05-06"}]